Haptoglobin Genotype and Its Role in Diabetic Cardiovascular Disease

1.

Preis, S. R., Hwang, S. J., Coady, S., Pencina, M. J., D'Agostino, R. B., Sr., Savage, P. J., Levy, D., & Fox, C. S. (2009). Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation, 119, 1728–1735.PubMedCrossRef

2.

Franco, O. H., Steyerberg, E. W., Hu, F. B., Mackenbach, J., & Nusselder, W. (2007). Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Archives of Internal Medicine, 167, 1145–1151.PubMedCrossRef

3.

Gu, K., Cowie, C. C., & Harris, M. I. (1998). Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care, 21, 1138–1145.PubMedCrossRef

4.

Centers for Disease Control and Prevention. (2011). National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention.

5.

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Division of Health Interview Statistics, data from the National Health Interview Survey. Data computed by personnel in the CDC's Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion.

6.

Gregg, E. W., Gu, Q., Cheng, Y. J., Narayan, K. M., & Cowie, C. C. (2007). Mortality trends in men and women with diabetes, 1971 to 2000. Annals of Internal Medicine, 147, 149–155.PubMed

7.

Pambianco, G., Costacou, T., Ellis, D., Becker, D. J., Klein, R., & Orchard, T. J. (2006). The 30-year natural history of type 1 diabetes complications. The Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes, 55, 1463–1469.PubMedCrossRef

8.

Imperatore, G., Cadwell, B. L., Geiss, L., Saadinne, J. B., Williams, D. E., Ford, E. S., Thompson, T. J., Narayan, K. M., & Gregg, E. W. (2004). Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination surveys, 1971–2000. American Journal of Epidemiology, 160, 531–539.PubMedCrossRef

9.

Krolewski, A. S., Warram, J. H., Christlieb, A. R., Busick, E. J., & Kahn, C. R. (1985). The changing natural history of nephropathy in type I diabetes. American Journal of Medicine, 78, 785–794.PubMedCrossRef

10.

Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H. C., Miller, M. E., Byington, R. P., Goff, D. C., Jr., Bigger, J. T., Buse, J. B., Cushman, W. C., Genuth, S., Ismail-Beigi, F., Grimm, R. H., Jr., Probstfield, J. L., Simons-Morton, D. G., & Friedewald, W. T. (2008). Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine, 358, 2545–2559.PubMedCrossRef

11.

ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D., Hamet, P., Harrap, S., Heller, S., Liu, L., Mancia, G., Mogensen, C. E., Pan, C., Poulter, N., Rodgers, A., Williams, B., Bompoint, S., de Galan, B. E., Joshi, R., & Travert, F. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine, 358(24), 2560–2572.PubMedCrossRef

12.

Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., Warren, S. R., Goldman, S., McCarren, M., Vitek, M. E., Henderson, W. G., Huang, G. D., & VADT Investigators. (2009). Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine, 360(2), 129–139.PubMedCrossRef

13.

Marre, M. (1999). Genetics and the prediction of complications in type 1 diabetes. Diabetes Care, 22(Suppl. 2), B53–B58.PubMed

14.

Ruiz, J. (1997). Diabetes mellitus and late complications: influence of genetic factors. Diabetes & Metabolism, 23(Suppl. 2), 57–63.

15.

Pignoli, P., Tremoli, E., Poli, A., et al. (1986). Intimal plus medial thickness of arterial wall: a direct measurement with ultrasound imaging. Circulation, 74, 1399–1406.PubMedCrossRef

16.

Persson, J., Stavenow, L., Wikstrand, J., et al. (1992). Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size. Arteriosclerosis and Thrombosis, 12, 261–266.PubMedCrossRef

17.

Carr, J. J., Crouse, J. R., Goff, D. C., Burke, G. L., et al. (2000). Evaluation of subsecond gated helical CT for quantification of coronary artery calcium and comparison with electron beam CT. American Journal of Roentgenology, 174, 915–921.PubMed

18.

Raggi, P., Callister, T. Q., Cooil, B., He, Z. X., Lippolis, N. J., Russo, D. J., Zelinger, A., & Mahmarian, J. J. (2000). Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation, 101, 850–855.PubMedCrossRef

19.

Edmonds, M. E. (2000). Medial arterial calcification and diabetes mellitus. Zeitschrift fur Kardiologie, 89(Suppl. 2), 101–104.PubMedCrossRef

20.

Lange, L. A., Bowden, D. W., Langefeld, C. D., Wagenknecht, L. E., Carr, J. J., Rich, S. S., Riley, W. A., & Freedman, B. I. (2002). Heritability of carotid artery intima–medial thickness in type 2 diabetes. Stroke, 33(7), 1876–1881.PubMedCrossRef

21.

Wagenknecht, L. E., Bowden, D. W., Carr, J. J., Langefeld, C. D., Freedman, B. I., & Rich, S. S. (2001). Familial aggregation of coronary artery calcium in families with type 2 diabetes. Diabetes, 50, 861–866.PubMedCrossRef

22.

Polonovski, M., & Jayle, M. F. (1938). Existence dans le plasma sanguine d’une substance activant l’action peroxydasique de l’hémoglobine. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales, 129, 457–460.

23.

Polonovski, M., & Jayle, M. F. (1940). Sur la préparation d'une nouvelle fraction des protéines plasmatiques l'haptoglobine. Compt Rend Acad Sci, 211, 517–519.

24.

Kalmovarin, N., Friedrichs, W. E., O'Brien, H. V., Linehan, L. A., Bowman, B. H., & Yang, F. (1991). Extrahepatic expression of plasma protein genes during inflammation. Inflammation, 15, 369–379.PubMedCrossRef

25.

Yang, F., Friedrichs, W. E., Navarijo-Ashbaugh, A. L., deGraffenried, L. A., Bowman, B. H., & Coalson, J. J. (1995). Cell type-specific and inflammatory-induced expression of haptoglobin gene in lung. Laboratory Investigation, 73(3), 433–440.PubMed

26.

Friedrichs, W. E., Navarijo-Ashbaugh, A. L., Bowman, B. H., & Yang, F. (1995). Expression and inflammatory regulation of haptoglobin gene in adipocytes. Biochemical and Biophysical Research Communications, 209, 250–256.PubMedCrossRef

27.

Kanakoudi, F., Drossou, V., Tzimouli, V., Diamanti, E., Konstantinidis, T., Germenis, A., & Kremenopoulos, G. (1995). Serum concentrations of 10 acute-phase proteins in healthy term and preterm infants from birth to age 6 months. Clinical Chemistry, 41, 605–608.PubMed

28.

Gabay, C., & Kushner, I. (1999). Mechanisms of disease: acute-phase proteins and other systemic responses to inflammation. New Engl J Med, 340, 448–454.PubMedCrossRef

29.

Bowman, B. H., & Kurosky, A. (1982). Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Advances in Human Genetics, 12, 189–261.PubMedCrossRef

30.

Langlois, M. R., & Delanghe, J. R. (1996). Biological and clinical significance of haptoglobin polymorphism in humans. Clinical Chemistry, 42, 1589–1600.PubMed

31.

Graversen, J. H., Madsen, M., & Moestrup, S. K. (2002). CD163: a signal receptor scavenging haptoglobin–hemoglobin complexes from plasma. The International Journal of Biochemistry & Cell Biology, 34(4), 309–314.CrossRef

32.

Garby, L., & Noyes, W. D. (1959). Studies on hemoglobin metabolism: I. The kinetic properties of the plasma hemoglobin pool in normal man. The Journal of Clinical Investigation, 38, 1479–1483.PubMedCrossRef

33.

Sadrzadeh, S. M. H., Graf, E., Panter, S. S., Hallaway, P. E., & Eaton, J. W. (1984). Hemoglobin: a biologic Fenton reagent. Journal of Biological Chemistry, 259, 14354–14356.PubMed

34.

Nakhoul, F. M., Miller-Lotan, R., Awad, H., Asleh, R., Kheir, J., Nakhoul, N., Asaf, R., Abu-Saleh, N., & Levy, A. P. (2009). Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus. American Journal of Physiology. Renal Physiology, 296, F830–F838.PubMedCrossRef

35.

Dessy, C., & Ferron, O. (2004). Pathophysiological roles of nitric oxide: in the heart and the coronary vasculature. Current Medical Chemistry—Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 3, 207–216.CrossRef

36.

Azarov, I., He, X., Jeffers, A., Basu, S., Ucer, B., Hantgan, R. R., Levy, A., & Kim-Shapiro, D. B. (2008). Rate of nitric oxide scavenging by hemoglobin bound to haptoglobin. Nitric Oxide, 18, 296–302.PubMedCrossRef

37.

Orchard, T. J., Costacou, T., Kretowski, A., & Nesto, R. W. (2006). Type 1 diabetes and coronary artery disease. Diabetes Care, 29, 2528–2538.PubMedCrossRef

38.

Yu, Y., Thorpe, S. R., Jenkins, A. J., Shaw, J. N., Sochaski, M. A., McGee, D., Aston, C. E., Orchard, T. J., Silvers, N., Peng, Y. G., McKnight, J. A., Baynes, J. W., Lyons, T. J., & The DCCT/EDIC Research Group. (2006). Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes. Diabetologia, 49, 2488–2498.PubMedCrossRef

39.

Endemann, D. H., & Schiffrin, E. L. (2004). Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Current Hypertension Reports, 6, 85–89.PubMedCrossRef

40.

Smithies, O. (1955). Zone electrophoresis in starch gels: group variation in the serum proteins of normal human adults. The Biochemical Journal, 61, 629–641.PubMed

41.

Wejman, J. C., Hovsepian, D., Wall, J. S., Hainfeld, J. F., & Greer, J. (1984). Structure and assembly of haptoglobin polymers by electron microscopy. Journal of Molecular Biology, 174, 343–368.PubMedCrossRef

42.

Carter, K., & Worwood, M. (2007). Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. International Journal of Laboratory Hematology, 29(2), 92–110.PubMedCrossRef

43.

Asleh, R., Marsh, S., Shilkrut, M., Binah, O., Guetta, J., Lejbkowicz, F., Enav, B., Shehadeh, N., Kanter, Y., Lache, O., Cohen, O., Levy, N. S., & Levy, A. P. (2003). Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circulation Research, 92, 1193–1200.PubMedCrossRef

44.

Melamed-Frank, M., Lache, O., Enav, B. I., Szafranek, T., Levy, N. S., Ricklis, R. M., & Levy, A. P. (2001). Structure–function analysis of the antioxidant properties of haptoglobin. Blood, 98, 3693–3698.PubMedCrossRef

45.

Asleh, R., Guetta, J., Kalet-Litman, S., Miller-Lotan, R., & Levy, A. P. (2005). Haptoglobin genotype and diabetes dependent differences in iron mediated oxidative stress in vitro and in vivo. Circulation Research, 96, 435–441.PubMedCrossRef

46.

Levy, A. P., Purushothaman, K. R., Levy, N. S., Purushothaman, M., Strauss, M., Asleh, R., Marsh, S., Cohen, O., Moestrup, S. K., Moller, H. J., Zias, E. A., Benhayon, D., Fuster, V., & Moreno, P. R. (2007). Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circulation Research, 101, 106–110.PubMedCrossRef

47.

Asleh, R., Blum, S., Kalet-Litman, S., Alshiek, J., Miller-Lotan, R., Asaf, R., Rock, W., Aviram, M., Milman, U., Shapira, C., Abassi, Z., & Levy, A. P. (2008). Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes, 57, 2794–2800.PubMedCrossRef

48.

Kunitake, S. T., Carilli, C. T., Lau, K., Protter, A. A., Naya-Vigne, J., & Kane, J. P. (1994). Identification of proteins associated with apolipoprotein A-I-containing lipoproteins purified by selected-affinity immunosorption. Biochemistry, 33, 1988–1993.PubMedCrossRef

49.

Porta, A., Cassano, E., Balestrieri, M., Bianco, M., Picone, R., De Stefano, C., & Abrescia, P. (1999). Haptoglobin transport into human ovarian follicles and its binding to apolipoprotein A-1. Zygote, 7, 67–77.PubMedCrossRef

50.

Spagnuolo, M. S., Cigliano, L., D'Andrea, L. D., Pedone, C., & Abrescia, P. (2005). Assignment of the binding site for haptoglobin on apolipoprotein A-I. Journal of Biological Chemistry, 280, 1193–1198.PubMedCrossRef

51.

Watanabe, J., Chou, K. J., Liao, J. C., Miao, Y., Meng, H. H., Ge, H., Grijalva, V., Hama, S., Kozak, K., Buga, G., Whitelegge, J. P., Lee, T. D., Farias-Eisner, R., Navab, M., Fogelman, A. M., & Reddy, S. T. (2007). Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. Journal of Biological Chemistry, 282, 23698–23707.PubMedCrossRef

52.

Watanabe, J., Grijalva, V., Hama, S., Barbour, K., Berger, F. G., Navab, M., Fogelman, A. M., & Reddy, S. T. (2009). Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. Journal of Biological Chemistry, 284, 18292–18301.PubMedCrossRef

53.

Asleh, R., & Levy, A. P. (2005). In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vascular Health and Risk Management, 1, 19–28.PubMedCrossRef

54.

Conway, B., Fried, L., & Orchard, T. J. (2008). Hemoglobin and overt nephropathy complications in type 1 diabetes. Annals of Epidemiology, 18, 147–155.PubMedCrossRef

55.

Levy, A. P., Hochberg, I., Jablonski, K., Resnick, H. E., Lee, E. T., Best, L., Howard, B. V., & Strong Heart Study. (2002). Haptoglobin genotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study. Journal of the American College of Cardiology, 40, 1984–1990.PubMedCrossRef

56.

Roguin, A., Koch, W., Kastrati, A., Aronson, D., Schomig, A., & Levy, A. P. (2003). Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care, 26, 2628–2631.PubMedCrossRef

57.

Suleiman, M., Aronson, D., Asleh, R., Kapeliovich, M. R., Roguin, A., Meisel, S. R., Shochat, M., Sulieman, A., Reisner, S. A., Markiewicz, W., Hammerman, H., Lotan, R., Levy, N. S., & Levy, A. P. (2005). Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes, 54, 2802–2806.PubMedCrossRef

58.

Milman, U., Blum, S., Shapira, C., Aronson, D., Miller-Lotan, R., Anbinder, Y., Alshiek, J., Bennett, L., Kostenko, M., Landau, M., Keidar, S., Levy, Y., Khemlin, A., Radan, A., & Levy, A. P. (2008). Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 341–347.PubMedCrossRef

59.

Costacou, T., Ferrell, R. E., & Orchard, T. J. (2008). Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes, 57, 1702–1706.PubMedCrossRef

60.

Simpson, M., Snell-Bergeon, J. K., Kinney, G. L., Lache, O., Miller-Lotan, R., Anbinder, Y., Rewers, M. J., & Levy, A. P. (2011). Haptoglobin genotype predicts development of coronary artery calcification in a prospective cohort of patients with type 1 diabetes. Cardiovascular Diabetology, 10, 99.PubMedCrossRef

61.

Levy, A. P., Levy, J. E., Kalet-Litman, S., Miller-Lotan, R., Levy, N. S., Asaf, R., Guetta, J., Yang, C., Purushothaman, K. R., Fuster, V., & Moreno, P. R. (2007). Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 134–140.PubMedCrossRef

62.

Kalet-Litman, S., Moreno, P. R., & Levy, A. P. (2010). The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque. Atherosclerosis, 209, 28–31.PubMedCrossRef

63.

Moreno, P. R., Purushothaman, K. R., Purushothaman, M., Muntner, P., Levy, N. S., Fuster, V., Fallon, J. T., Lento, P. A., Winterstern, A., & Levy, A. P. (2008). Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. Journal of the American College of Cardiology, 52, 1049–1051.PubMedCrossRef

64.

Lioupis, C., Barbatis, C., Drougou, A., Koliaraki, V., Mamalaki, A., Klonaris, C., Georgopoulos, S., Andrikopoulos, V., & Bastounis, E. (2011). Association of haptoglobin genotype and common cardiovascular risk factors with the amount of iron in atherosclerotic carotid plaques. Atherosclerosis, 216, 131–138.PubMedCrossRef

65.

Asleh, R., Miller-Lotan, R., Aviram, M., Hayek, T., Yulish, M., Levy, J. E., Miller, B., Blum, S., Milman, U., Shapira, C., & Levy, A. P. (2006). Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circulation Research, 99, 1419–1425.PubMedCrossRef

66.

Orchard, T. J. (1991). Dyslipoproteinemia and diabetes. Endocrinology and Metabolism Clinics of North America, 19, 361–380.

67.

Costacou, T., Evans, R. W., Orchard, T. J. (2011) High density lipoprotein cholesterol: is higher always better? Journal of Clinical Lipidology, 5(5), 387–394. PMCID: PMC3190122.

68.

Brouwers, A., Langlois, M., Delanghe, J., Billiet, J., De Buyzere, M., Vercaemst, R., Rietzschel, E., Bernard, D., & Blaton, V. (2004). Oxidized low-density lipoprotein, iron stores, and haptoglobin polymorphism. Atherosclerosis, 176(1), 189–195.PubMedCrossRef

69.

Libby, P., Ridker, P. M., & Hansson, G. K. (2009). Inflammation in atherosclerosis: from pathophysiology to practice. Journal of the American College of Cardiology, 54, 2129–2138.PubMedCrossRef

70.

Philippidis, P., Mason, J. C., Evans, B. J., Nadra, I., Taylor, K. M., Haskard, D. O., & Landis, R. C. (2004). Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte–macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circulation Research, 94(1), 119–126.PubMedCrossRef

71.

Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., Parfrey, P., Pfeffer, M., Raij, L., Spinosa, D. J., Wilson, P. W., & American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. (2003). Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension, 42, 1050–1065.PubMedCrossRef

72.

Dinneen, S. F., & Gerstein, H. C. (1997). The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Archives of Internal Medicine, 157, 1413–1418.PubMedCrossRef

73.

Jensen, T., Borch-Johnsen, K., Kofoed-Enevoldsen, A., & Deckert, T. (1987). Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia, 30, 144–148.PubMedCrossRef

74.

Messent, J. W. C., Elliott, T. G., Hill, R. D., Jarrett, R. J., Keen, H., & Viberti, G. C. (1992). Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney International, 41, 836–839.PubMedCrossRef

75.

Tuomilehto, J., Borch-Johnsen, K., Molarius, A., Forsén, T., Rastenyte, D., Sarti, C., & Reunanen, A. (1998). Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia, 41, 784–790.PubMedCrossRef

76.

Torffvit, O., Lövestam-Adrian, M., Agardh, E., & Agardh, C.-D. (2005). Nephropathy, but not retinopathy, is associated with the development of heart disease in type I diabetes: a 12-year observation study of 462 patients. Diabetic Medicine, 22, 723–729.PubMedCrossRef

77.

Costacou, T., Ferrell, R. E., Ellis, D., & Orchard, T. J. (2009). Haptoglobin genotype and renal function decline in type 1 diabetes. Diabetes, 58, 2904–2909.PubMedCrossRef

78.

Kramer, H. J., Nguyen, Q. D., Curhan, G., & Hsu, C. Y. (2003). Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA, 289, 3273–3277.PubMedCrossRef

79.

Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I., & Holman, R. R. (2006). UKPDS Study risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes, 55, 1832–1839.PubMedCrossRef

80.

Costacou, T., Ellis, D., Fried, L., & Orchard, T. J. (2007). Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. American Journal of Kidney Diseases, 50, 721–732.PubMedCrossRef

81.

Hiller, R., Sperduto, R. D., Podgor, M. J., Ferris, F. L., 3rd, & Wilson, P. W. (1988). Diabetic retinopathy and cardiovascular disease in type II diabetics. The Framingham Heart Study and the Framingham Eye Study. American Journal of Epidemiology, 128(2), 402–409.PubMed

82.

Wong, T. Y., Klein, R., Klein, B. E. K., Tielsch, J. M., Hubbard, L., & Nieto, F. J. (2001). Retinal microvascular abnormalities and their relationship with hypertension, cardiovascular disease, and mortality. Survey of Ophthalmology, 46, 59–80.PubMedCrossRef

83.

Cheung, N., Bluemke, D. A., Klein, R., Sharrett, A. R., Islam, F. M., Cotch, M. F., Klein, B. E., Criqui, M. H., & Wong, T. Y. (2007). Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. Journal of the American College of Cardiology, 50, 48–55.PubMedCrossRef

84.

Wong, T. Y., Wong, T. Y., Cheung, N., Islam, A. F. M., Klein, R., Criqui, M. H., Cotch, M. F., Carr, J. J., Klein, B. E., & Sharrett, A. R. (2008). Relation of retinopathy to coronary artery calcification: the multi-ethnic study of atherosclerosis. American Journal of Epidemiology, 167(1), 51–58.PubMedCrossRef

85.

Kawasaki, R., Cheung, N., Islam, F. M., Klein, R., Klein, B. E., Cotch, M. F., Sharrett, A. R., O'Leary, D., Wong, T. Y., & Multi-Ethnic Study of Atherosclerosis. (2011). Is diabetic retinopathy related to subclinical cardiovascular disease? Ophthalmology, 118, 860–865.PubMedCrossRef

86.

Giacco, F., & Brownlee, M. (2010). Oxidative stress and diabetic complications. Circulation Research, 107(9), 1058–1070.PubMedCrossRef

87.

Goldenberg-Cohen, N., Gabbay, M., Dratviman-Storobinsky, O., Reich, E., Axer-Siegel, R., Weinberger, D., & Gabbay, U. (2011). Does haptoglobin genotype affect early onset of diabetic retinopathy in patients with type 2 diabetes? Retina, 31(8), 1574–1580.PubMedCrossRef

88.

Rapola, J. M., Virtamo, J., Haukka, J. K., Heinonen, O. P., Albanes, D., Taylor, P. R., & Huttunen, J. K. (1996). Effect of vitamin E and beta carotene on the incidence of angina pectoris: a randomized, double-blind, controlled trial. JAMA, 275, 693–698.PubMedCrossRef

89.

Yusuf, S., Dagenais, G., Pogue, J., Bosch, J., Sleight, P., & for the Heart Outcomes Prevention Evaluation Study Investigators. (2000). Vitamin E supplementation and cardiovascular events in high-risk patients. The New England Journal of Medicine, 342, 154–160.PubMedCrossRef

90.

Lee, I. M., Cook, N. R., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005). Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA, 294(1), 56–65.PubMedCrossRef

91.

de Gaetano, G., & for the Collaborative Group of the Primary Prevention Project. (2001). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet, 357, 89–95.PubMedCrossRef

92.

Virtamo, J., Rapola, J. M., Ripatti, S., Heinonen, O. P., Taylor, P. R., Albanes, D., & Huttunen, J. K. (1998). Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Archives of Internal Medicine, 158, 668–675.PubMedCrossRef

93.

Hodis, H. N., Mack, W. J., LaBree, L., Mahrer, P. R., Sevanian, A., Liu, C. R., Liu, C. H., Hwang, J., Selzer, R. H., Azen, S. P., & for the VEAPS Research Group. (2002). Alpha-tocopherol supplementation in healthy individuals reduces low density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation, 106, 1453–1459.PubMedCrossRef

94.

Cook, N. R., Albert, C. M., Gaziano, J. M., Zaharris, E., MacFadyen, J., Danielson, E., Buring, J. E., & Manson, J. E. (2007). A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women’s Antioxidant Cardiovascular Study. Archives of Internal Medicine, 167, 1610–1618.PubMedCrossRef

95.

Levy, A. P., Gerstein, H., Lotan, R., Ratner, R., McQueen, M., Lonn, E., & Pogue, J. (2004). The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care, 27, 2767.PubMedCrossRef

96.

Blum, S., Vardi, M., Levy, N. S., Miller-Lotan, R., & Levy, A. P. (2010). The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis, 211, 25–27.PubMedCrossRef

97.

Blum, S., Milman, U., Shapira, C., Miller-Lotan, R., Bennett, L., Kostenko, M., Landau, M., Keidar, S., Levy, Y., Khemlin, A., Radan, A., & Levy, A. P. (2008). Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, e18–e20.PubMedCrossRef

98.

Blum, S., Milman, U., Shapira, C., Levy, N. S., Miller-Lotan,. R., Levy, A. P. (2010) Vitamin E supplementation may provide cardiovascular benefit to Hp 2-2 diabetic individuals over and above that which can be obtained by treating to target for LDL and HbA1c. Circulation, 122, A10490 (abstract).

99.

Engelen, W., Manuel-y-Keenoy, B., Vertommen, J., De Leeuw, I., & Van Gaal, L. (2005). Effects of micronized finofibrate and vitamin E on in vitro oxidation of lipoproteins in patients with type 1 diabetes mellitus. Diabetes & Metabolism, 31, 197–204.CrossRef

100.

Farbstein, D., Blum, S., Pollak, M., Asaf, R., Viener, H. L., Lache, O., Asleh, R., Miller-Lotan, R., Barkay, I., Star, M., Schwartz, A., Kalet-Littman, S., Ozeri, D., Vaya, J., Tavori, H., Vardi, M., Laor, A., Bucher, S. E., Anbinder, Y., Moskovich, D., Abbas, N., Perry, N., & Levy, A. P. (2011). Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype. Atherosclerosis, 219, 240–244.PubMedCrossRef

101.

Levy, A. P., Friedenberg, P., Lotan, R., Ouyang, P., Tripputi, M., Higginson, L., Cobb, F. R., Tardif, J. C., Bittner, V., & Howard, B. V. (2004). The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women. Diabetes Care, 27(4), 925–930.PubMedCrossRef

102.

Waters, D. D., Alderman, E. L., Hsia, J., Howard, B. V., Cobb, F. R., Rogers, W. J., Ouyang, P., Thompson, P., Tardif, J. C., Higginson, L., Bittner, V., Steffes, M., Gordon, D. J., Proschan, M., Younes, N., & Verter, J. I. (2002). Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA, 288, 2432–2440.PubMedCrossRef

103.

Mowri, H. O., Frei, B., & Keaney, J. F., Jr. (2000). Glucose enhancement of LDL oxidation is strictly metal ion dependent. Free Radical Biology & Medicine, 29(9), 814–824.CrossRef

104.

Asleh, R., & Levy, A. P. (2010). Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype. Antioxidants & Redox Signaling, 12(2), 209–217.CrossRef

105.

Klein, E. A., Thompson, I. M., Jr., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., Karp, D. D., Lieber, M. M., Walther, P. J., Klotz, L., Parsons, J. K., Chin, J. L., Darke, A. K., Lippman, S. M., Goodman, G. E., Meyskens, F. L., Jr., & Baker, L. H. (2011). Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 306(14), 1549–1556.PubMedCrossRef

106.

Heinonen, O. P., Albanes, D., Virtamo, J., Taylor, P. R., Huttunen, J. K., Hartman, A. M., Haapakoski, J., Malila, N., Rautalahti, M., Ripatti, S., Mäenpää, H., Teerenhovi, L., Koss, L., Virolainen, M., & Edwards, B. K. (1998). Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. Journal of the National Cancer Institute, 90(6), 440–446.PubMedCrossRef

107.

Gaziano, J. M., Glynn, R. J., Christen, W. G., Kurth, T., Belanger, C., MacFadyen, J., Bubes, V., Manson, J. E., Sesso, H. D., & Buring, J. E. (2009). Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA, 301(1), 52–62.PubMedCrossRef

108.

Lonn, E., Bosch, J., Yusuf, S., Sheridan, P., Pogue, J., Arnold, J. M., Ross, C., Arnold, A., Sleight, P., Probstfield, J., Dagenais, G. R., & HOPE and HOPE-TOO Trial Investigators. (2005). Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA, 293(11), 1338–1347.PubMedCrossRef

109.

Brigelius-Flohé, R., & Traber, M. G. (1999). Vitamin E: function and metabolism. The FASEB Journal, 13(10), 1145–1155.

110.

Traber, M. G., Elsner, A., & Brigelius-Flohé, R. (1998). Synthetic as compared to natural vitamin E is preferentially excreted as α-CEHC in human urine: studies using deuterated α-tocopheryl acetates. FEBS, 437, 145–148.CrossRef

111.

Yamauchi, J., Iwamoto, T., Kida, S., Masushige, S., Yamada, K., & Esashi, T. (2001). Tocopherol-associated protein is a ligand-dependent transcriptional activator. Biochemical and Biophysical Research Communications, 285(2), 295–299.PubMedCrossRef

112.

Institute of Medicine (2000). Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington: National Academies Press.

Springer Medizin

Haptoglobin Genotype and Its Role in Diabetic Cardiovascular Disease

Abstract

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Myokarditis nach Infekt – Richtig schwierig wird es bei Profisportlern

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Erratum to: Routine Invasive Versus Conservative Management Strategies in Acute Coronary Syndrome: Time for a “Hybrid” Approach

Diabetic Complications: Current Challenges and Opportunities

The Value of Visfatin in the Prediction of Metabolic Syndrome: A Multi-Factorial Analysis

What Do We Know and We Do Not Know About Cardiovascular Autonomic Neuropathy in Diabetes